NOT KNOWN FACTS ABOUT MBL77

mutations provided the fact that, as discussed below, CLL therapy relies over the presence or absence of those mutations. The existing consensus is that, besides clonal mutations, subclonal mutations which has a variant allelic frequency ranging from 5 to ten% (and so down below the threshold of detection by conventional molecular strategies) is al